CHARLOTTESVILLE, Va., June 23, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced positive effects from its second Oxygenation Trial, the Altitude Trial.
Read more at globenewswire.comDiffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
Globe Newswire - Press Release 
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Blackrock%20Inc_%20logo%20on%20building-%20by%20Tada%20Images%20via%20Shutterstock.jpg)
/2d%20illustration%20of%20Cloud%20computing%20by%20Blackboard%20via%20Shutterstock.jpg)
/Amazon_com%20Inc_%20storefront%20by-%20%20Markus%20Mainka%20via%20Shutterstock.jpg)